Rani Therapeutics Soars 12.95% on Obesity Treatment Breakthroughs

On May 19, 2025, Rani Therapeutics' stock surged by 12.95% in pre-market trading, reflecting significant investor interest and optimism in the company's recent developments.

Rani Therapeutics has been the subject of strategic advancements in the obesity treatment market. Analyst Michael Okunewitch from Maxim Group maintained a Buy rating on the stock, citing the company's potential in this sector. The Phase 1 study of RT-114, a promising candidate in the GLP-1/GLP-2 space, has shown favorable bioavailability in preclinical studies, positioning it to replicate the therapeutic benefits of existing subcutaneous formulations.

Additionally, Rani's innovative RaniPill technology has successfully delivered semaglutide with comparable efficacy to injectable forms. This innovation could offer a competitive edge as the obesity market expands, especially with the impending expiration of semaglutide patents. The vast obesity market, coupled with Rani’s strategic focus on developing a diverse oral obesity pipeline, underscores the potential for significant market penetration and revenue growth, justifying the Buy rating.

In another report released on May 14, Canaccord Genuity also reiterated a Buy rating on the stock with a $9.00 price target, further bolstering investor confidence in Rani Therapeutics' future prospects.